Literature DB >> 16527337

Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone.

Tatsuya Ohno1, Shingo Kato, Masaru Wakatsuki, Shin-Ei Noda, Chiemi Murakami, Misako Nakamura, Hirohiko Tsujii.   

Abstract

OBJECTIVE: To investigate the temporal patterns of anorexia, diarrhea, weight loss, and leukopenia in chemoradiation therapy (CRT) for cervical cancer compared with radiation therapy (RT) alone.
METHODS: Acute toxicities in 43 patients receiving RT alone and 40 patients receiving CRT were retrospectively analyzed. Patients were treated with a combination of external beam irradiation and high-dose rate intracavitary irradiation. Cisplatin was given once a week for 5 weeks concurrently with the external beam irradiation. CRT was divided into low-dose CRT group (cisplatin, 20-30 mg/m(2), n = 16) and high-dose CRT group (cisplatin, 35-40 mg/m(2), n = 24). Toxicities were evaluated before, every week up to 7 weeks during the cycle, and 12 weeks after initial irradiation, according to the National Cancer Institute Common Toxicity Criteria version 2.
RESULTS: In the high-dose CRT group, anorexia during the first 5 weeks, leukopenia after 5 weeks, and weight loss after 3 weeks were significantly higher than those in the RT alone group. In the low-dose CRT group, anorexia between 1 and 2 weeks, leukopenia after 5 weeks, and weight loss between 3 and 4 weeks were significantly higher than those in the RT alone group. Diarrhea between 1 and 2 weeks in the high-dose CRT group (P = 0.037, P = 0.025) and between 2 and 3 weeks in the low-dose CRT group (P = 0.015, P = 0.036) was significantly lower compared with RT alone.
CONCLUSION: These data can help us understand when patients are likely to develop maximal toxicities and to manage them with optimal timing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527337     DOI: 10.1016/j.ygyno.2006.01.048

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  An overview of the European Society of Medical Oncology (ESMO) Symposium on Cancer and Nutrition 2009: from cancer prevention to nutrition support to alleviating suffering in patients with advanced cancer.

Authors:  Florian Strasser; An Van den Broek; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2011-09-01       Impact factor: 3.603

2.  The Role of Magnesium Supplementation in Cisplatin-induced Nephrotoxicity in a Rat Model: No Nephroprotectant Effect.

Authors:  Farzaneh Ashrafi; Sara Haghshenas; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Fatemeh Eshraghi-Jazi; Zahra Pezeshki; Tahereh Safari
Journal:  Int J Prev Med       Date:  2012-09

3.  The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model.

Authors:  Fatemeh Eshraghi-Jazi; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Maryam Haghighi; Zahra Pezeshki; Tahereh Safari; Farzaneh Ashrafi
Journal:  J Res Med Sci       Date:  2011-11       Impact factor: 1.852

Review 4.  A New Strategy Using Rikkunshito to Treat Anorexia and Gastrointestinal Dysfunction.

Authors:  Yayoi Saegusa; Tomohisa Hattori; Miwa Nahata; Chihiro Yamada; Hiroshi Takeda
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-03       Impact factor: 2.629

5.  Effect of oral administration of magnesium on Cisplatin-induced nephrotoxicity in normal and streptozocin-induced diabetic rats.

Authors:  Nepton Soltani; Mehdi Nematbakhsh; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Farzaneh Ashrafi
Journal:  Nephrourol Mon       Date:  2013-08-20

6.  Vitamin e is a nephroprotectant agent in male but not in female in a model of Cisplatin-induced nephrotoxicity.

Authors:  Sima Jilanchi; Mehdi Nematbakhsh; Mehrnoosh Bahadorani; Ardeshir Talebi; Fatemeh Eshraghi-Jazi; Azam Mansouri; Farzaneh Ashrafi
Journal:  ISRN Nephrol       Date:  2013-06-23

7.  Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy.

Authors:  Takahiro Oike; Tatsuya Ohno; Shin-ei Noda; Hiro Sato; Tomoaki Tamaki; Hiroki Kiyohara; Ken Ando; Takashi Nakano
Journal:  J Radiat Res       Date:  2012-12-14       Impact factor: 2.724

8.  Inhibition of Nitric Oxide Synthase by L-NAME Promotes Cisplatin-Induced Nephrotoxicity in Male Rats.

Authors:  Fatemeh Moslemi; Mehdi Nematbakhsh; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Hamid Nasri; Farzaneh Ashrafi; Maryam Moeini; Azam Mansouri; Zahra Pezeshki
Journal:  ISRN Toxicol       Date:  2013-09-17

9.  Effect of Γ-aminobutyric acid on kidney injury induced by renal ischemia-reperfusion in male and female rats: Gender-related difference.

Authors:  Marzieh Vafapour; Mehdi Nematbakhsh; Ramesh Monajemi; Safoora Mazaheri; Ardeshir Talebi; Nahid Talebi; Soheyla Shirdavani
Journal:  Adv Biomed Res       Date:  2015-07-27

10.  Effects of Fennel Essential Oil on Cisplatin-induced Nephrotoxicity in Ovariectomized Rats.

Authors:  Safoora Mazaheri; Mehdi Nematbakhsh; Mehrnoosh Bahadorani; Zahra Pezeshki; Ardeshir Talebi; Ali-Reza Ghannadi; Farzaneh Ashrafi
Journal:  Toxicol Int       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.